-
Providence, RI--(BUSINESS WIRE)--Beech Tree Labs, Inc. announced today publication of data providing evidence that its novel product candidate addressing scarring and wound healing showed efficacy in a Mycobacterium tuberculosis (TB) animal model.
Based on substantial pre-clinical data...
-
Providence, RI--(BUSINESS WIRE)--Beech Tree Labs, Inc. announced today that it has initiated a Phase 1/2a clinical evaluation of its novel therapeutic agent, UISH001, for treating urinary incontinence (UI). This FDA-approved study is a 60 patient, placebo-controlled trial.
As referenced by the...
-
Providence, R.I.--(BUSINESS WIRE)--Beech Tree Labs, Inc. announced today the simultaneous closing of its over-subscribed Series B offering and its receipt of a U.S. government grant. The former funds, raised exclusively from private investors, are to be used to further the Company's two Phase 2 IND...
-
Providence, RI--(BUSINESS WIRE)--Beech Tree Labs, Inc. announced today that it has initiated a Phase 1/2a clinical evaluation of its novel therapeutic agent for treating recurrent oral herpes infections. This FDA-approved study is a 210 patient, multi-site, placebo-controlled trial of its agent BTL...
-
Providence, RI--(BUSINESS WIRE)--Beech Tree Labs, Inc., announced today that the FDA has approved its IND for a Phase 1/2a clinical evaluation of BTL-TML-HSV, a novel therapeutic agent for treating recurrent oral herpes infections. The study will be a 210 patient, multi-site, placebo-controlled...
-
Providence, RI--(BUSINESS WIRE)--Beech Tree Labs, Inc., announced today that the FDA has approved its IND for a 180 patient Phase 1/2a clinical evaluation of BTL-TML001, a novel therapeutic agent for treating acute influenza virus infections.
In the United States it is estimated that outbreaks of...
